WC 3016

Drug Profile

WC 3016

Alternative Names: WC3016

Latest Information Update: 24 Mar 2014

Price : $50

At a glance

  • Originator Warner Chilcott
  • Developer Actavis Inc
  • Class Contraceptives
  • Mechanism of Action Hormone modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pregnancy

Most Recent Events

  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
  • 31 Dec 2010 Discontinued - Preregistration for Pregnancy (Prevention) in USA (PO)
  • 27 Jan 2010 Warner Chilcott receives complete response letter from the FDA for WC 3016 in Contraception
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top